Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. Capricor ( ) is a biotechnology company developing transformative therapeutics for diseases.

Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives. Capricor is focused on the development of biologics, primarily cell and exosome-based technologies to treat or prevent a broad range of diseases. Our lead product is a cell therapy designed to treat Duchenne muscular dy

strophy (DMD), the most severe form of muscular dystrophy, which results in muscle degeneration and premature death. Capricor’s innovative exosome technology is focusing on engineering exosomes to treat or prevent diseases with high unmet medical needs. Our translational approach to product development is based on the strong research foundation provided by our academic partnerships with leading scientists at top-tier research institutions.

Capricor is proud to be presenting our HOPE-3 results at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual...
05/14/2026

Capricor is proud to be presenting our HOPE-3 results at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting being held this week in Boston (May 11–15). With over 2,000 abstracts showcasing the latest in cell and gene therapy, this is one of the premier gatherings in the industry — and we look forward to sharing our data. Click to see the full conference agenda: https://annualmeeting.asgct.org/program-workshops

Capricor just reported its first quarter 2026 financial results and provided a recent corporate update. Click here to re...
05/12/2026

Capricor just reported its first quarter 2026 financial results and provided a recent corporate update. Click here to read the full release: https://bit.ly/4udKQcy

Capricor will report its first quarter 2026 financial results and provide a recent corporate update on May 12 at 4:30 p....
05/04/2026

Capricor will report its first quarter 2026 financial results and provide a recent corporate update on May 12 at 4:30 p.m. ET.

Register for the webcast to stay up to date on our progress and key developments: https://bit.ly/3P1v5Ww

At the American Academy of Neurology (AAN) 2026 Annual Meeting in Chicago, Capricor will be presenting Phase 3 HOPE-3 re...
04/21/2026

At the American Academy of Neurology (AAN) 2026 Annual Meeting in Chicago, Capricor will be presenting Phase 3 HOPE-3 results for Deramiocel in a late-breaking oral presentation later today. The presentation highlights previously reported topline data demonstrating significant functional benefits in patients with Duchenne muscular dystrophy (DMD). For more information, please click https://bit.ly/4cXjCAt

Capricor is pleased to be attending the 38th Annual Roth Conference this week in Dana Point, California. The annual conf...
03/23/2026

Capricor is pleased to be attending the 38th Annual Roth Conference this week in Dana Point, California. The annual conference brings together more than 400 public and private companies, along with investors, for expert-led panels and keynotes across a range of multiple sectors.

We just reported our fourth quarter and full year 2025 financial results. Click here to read the release: https://bit.ly...
03/12/2026

We just reported our fourth quarter and full year 2025 financial results. Click here to read the release: https://bit.ly/4bKdCcP
Our quarterly conference call begins at 4:30 p.m. ET – join the webcast here: https://bit.ly/3NjKRLy

Yesterday at , we presented late-breaking data from the Phase 3 HOPE-3 trial highlighting Deramiocel’s potential impact...
03/12/2026

Yesterday at , we presented late-breaking data from the Phase 3 HOPE-3 trial highlighting Deramiocel’s potential impact on functional outcomes in Duchenne muscular dystrophy.
Read the full release: https://bit.ly/3NfTTcE

We’re pleased to be attending the 2026 MDA Conference this week in Orlando, Florida. This important meeting brings toget...
03/10/2026

We’re pleased to be attending the 2026 MDA Conference this week in Orlando, Florida. This important meeting brings together clinicians, researchers and patient advocates to discuss the latest developments in Duchenne muscular dystrophy (DMD) and other neuromuscular diseases.

Capricor will be featured in the late-breaking presentation on March 11 and will also be at Booth #407 during the meeting.
If you’re attending, please stop by and say hello.

Today we announced that the U.S. FDA has resumed review of our BLA for Deramiocel for the treatment of Duchenne muscular...
03/10/2026

Today we announced that the U.S. FDA has resumed review of our BLA for Deramiocel for the treatment of Duchenne muscular dystrophy and set a PDUFA target action date of August 22, 2026.
Click here to read the announcement: https://bit.ly/4bz2qk2

February 28 is Rare Disease Day 💜 Today, we stand with the more than 300 million people worldwide living with a rare dis...
02/28/2026

February 28 is Rare Disease Day 💜

Today, we stand with the more than 300 million people worldwide living with a rare disease — including those affected by Duchenne muscular dystrophy (DMD). At Capricor, our mission is clear: advance innovative therapies and work with urgency to bring new options to patients and families who need them most.

Today and every day, we remain focused on transforming innovation into hope.

Address

10865 Road To The Cure
San Diego, CA
92121

Website

Alerts

Be the first to know and let us send you an email when Capricor Therapeutics, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Capricor Therapeutics, Inc.:

Shortcuts

Featured

Share